Effect of Bifidobacterium animalis subsp. lactis GCL2505 on the physiological function of intestine in a rat model

Aoki, Ryo; Tsuchida, Sayaka; Arai, Y.; Ohno, Konatsu; Nishijima, Toshitaka; Mizutani, Takashi; Mikami, Yumiko; Ushida, Kazunari

doi:10.1002/fsn3.344

Cited by 22 publications

(16 citation statements)

References 50 publications

(78 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ability to improve the synchrony of contractions by decreasing dysmotility might explain why HN019 is also able to reduce the severity of weanling diarrhea associated with rotavirus and E. coli in a piglet model over the first 3 days post-weaning (Shu et al, 2001 ). A related strain (GCL2505) of the Bifidobacterium lactis species has recently been reported to slightly increase fecal output in a rat model of constipation induced by loperamide (Aoki et al, 2016 ).…”

Section: Discussionmentioning

confidence: 99%

Promotility Action of the Probiotic Bifidobacterium lactis HN019 Extract Compared with Prucalopride in Isolated Rat Large Intestine

et al. 2017

View full text Add to dashboard Cite

Attention is increasingly being focussed on probiotics as potential agents to restore or improve gastrointestinal (GI) transit. Determining mechanism of action would support robust health claims. The probiotic bacterium Bifidobacterium lactis HN019 reduces transit time, but its mechanisms of action and effects on motility patterns are poorly understood. The aim of this study was to investigate changes in GI motility induced by an extract of HN019 on distinct patterns of colonic motility in isolated rat large intestine, compared with a known promotility modulator, prucalopride. The large intestines from male Sprague Dawley rats (3–6 months) were perfused with Kreb's buffer at 37°C in an oxygenated tissue bath. Isometric force transducers recorded changes in circular muscle activity at four independent locations assessing contractile propagation between the proximal colon and the rectum. HN019 extract was perfused through the tissue bath and differences in tension and frequency quantified relative to pre-treatment controls. Prucalopride (1 μM) increased the frequency of propagating contractions (by 75 ± 26%) in the majority of preparations studied (10/12), concurrently decreasing the frequency of non-propagating contractions (by 50 ± 11%). HN019 extract had no effect on contractile activity during exposure (n = 8). However, following wash out, contraction amplitude of propagating contractions increased (by 55 ± 18%) in the distal colon, while the frequency of non-propagating proximal contractions decreased by 57 ± 7%. The prokinetic action of prucalopride increased the frequency of synchronous contractions along the length of colon, likely explaining increased colonic rate of transit in vivo. HN019 extract modified motility patterns in a different manner by promoting propagating contractile amplitude and inhibiting non-propagations, also demonstrating prokinetic activity consistent with the reduction of constipation by B. lactis HN019 in humans.

show abstract

Section: Discussionmentioning

confidence: 99%

Promotility Action of the Probiotic Bifidobacterium lactis HN019 Extract Compared with Prucalopride in Isolated Rat Large Intestine

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In addition, B. lactis GCL2505 reportedly caused a significant increase of IgA production and mucin secretion in the murine gut when compared with a type strain of a bifidobacterial species ( B. longum JCM1217 T ), and the proliferation level of the administered bifidobacteria in the intestine affected these physiological responses of the host [34]. IgA production and mucin secretion in the gut are associated with effective intestinal barrier function.…”

Section: Discussionmentioning

confidence: 99%

Effect of Bifidobacterium animalis ssp. lactis GCL2505 on visceral fat accumulation in healthy Japanese adults: a randomized controlled trial

Takahashi

Anzawa

Kazuyo

et al. 2016

Bioscience of Microbiota, Food and Health

Self Cite

View full text Add to dashboard Cite

Bifidobacterium animalis ssp. lactis GCL2505 (B. lactis GCL2505) is able to survive passage through the intestine and then proliferate, leading to an increase in the amount of gut bifidobacteria. In the present study, we evaluated the impact of B. lactis GCL2505 on abdominal visceral fat storage in overweight and mildly obese Japanese adults. This clinical study was a double-blind, randomized, placebo-controlled, parallel-group comparative trial performed for 12 weeks. Healthy Japanese subjects (N=137) with body mass indices ranging from 23 to 30 kg/m2 consumed either fermented milk containing B. lactis GCL2505 or a placebo every day, and then visceral and subcutaneous abdominal fat areas were measured by computed tomography as the primary endpoints. The number of fecal bifidobacteria was also measured. Visceral fat area, but not subcutaneous fat area, was significantly reduced from baseline at 8 and 12 weeks in the GCL2505 group, compared with the placebo group. The total number of fecal bifidobacteria was significantly increased in the GCL2505 group. These results indicate that B. lactis GCL2505 reduces abdominal visceral fat, a key factor associated with metabolic disorders. This finding suggests that this probiotic strain can potentially serve as a specific functional food to achieve visceral fat reduction in overweight or mildly obese individuals.

show abstract

“…longum JCM1217 T (BloJ), which have different properties in the gut, and intensively investigated their effects on metabolic parameters, global changes in the gut microbiota, and SCFA levels in mice. BlaG was originally isolated from the faeces of a healthy adult, and is reported to be a probiotic strain capable of proliferating in the gut 21 22 . BloJ is a type strain of Bifidobacterium longum that has been widely used in commercial probiotics 23 and is reported to protect the host from enteropathogenic infection through the production of acetate 24 , but is not capable of proliferating in the gut 22 .…”

mentioning

confidence: 99%

A proliferative probiotic Bifidobacterium strain in the gut ameliorates progression of metabolic disorders via microbiota modulation and acetate elevation

Aoki

Kamikado

Suda

et al. 2017

Sci Rep

Self Cite

174

124

View full text Add to dashboard Cite

The gut microbiota is an important contributor to the worldwide prevalence of metabolic syndrome (MS), which includes obesity and diabetes. The anti-MS effects exerted by Bifidobacterium animalis ssp. lactis GCL2505 (BlaG), a highly proliferative Bifidobacterium strain in the gut, and B. longum ssp. longum JCM1217T (BloJ) were comparatively examined. BlaG treatment reduced visceral fat accumulation and improved glucose tolerance, whereas BloJ had no effect on these parameters. Gut microbial analysis revealed that BlaG exerted stronger effects on the overall bacterial structure of the gut microbiota than BloJ, including enrichment of the genus Bifidobacterium. The levels of acetate and glucagon-like peptide-1 were increased by BlaG treatment in both the gut and plasma, but not by BloJ treatment. Correlation analysis suggested that the elevation of gut acetate levels by BlaG treatment plays a pivotal role in the BlaG-induced anti-MS effects. These findings indicated that BlaG, a highly viable and proliferative probiotic, improves metabolic disorders by modulating gut microbiota, which results in the elevation of SCFAs, especially acetate.

show abstract

Effect of Bifidobacterium animalis subsp. lactis GCL2505 on the physiological function of intestine in a rat model

Cited by 22 publications

References 50 publications

Promotility Action of the Probiotic Bifidobacterium lactis HN019 Extract Compared with Prucalopride in Isolated Rat Large Intestine

Promotility Action of the Probiotic Bifidobacterium lactis HN019 Extract Compared with Prucalopride in Isolated Rat Large Intestine

Effect of <i>Bifidobacterium animalis</i> ssp. <i>lactis</i> GCL2505 on visceral fat accumulation in healthy Japanese adults: a randomized controlled trial

A proliferative probiotic Bifidobacterium strain in the gut ameliorates progression of metabolic disorders via microbiota modulation and acetate elevation

Contact Info

Product

Resources

About